Navigation Links
The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus' Solicitation Efforts
Date:5/7/2009

us' proposed slate of nominees is primarily comprised of a group of individuals with whom he has had personal or professional dealings. We do not believe these individuals have the experience or qualifications to advance the interests of The Quigley Corporation and its stockholders. The background and expertise of his group includes financial services, marketing, construction and hospitality, as well as his personal physician. Karkus has nominated partisan individuals with minimal if any public company, pharmaceutical, manufacturing or other related experience. Simply put, they lack the necessary qualifications we believe are required to direct the future of The Quigley Corporation.

KARKUS HAS NEVER BOTHERED TO CONTACT THE BOARD OF DIRECTORS

Karkus has never attempted to engage in a constructive dialogue with your incumbent Board about steps he believes should be taken to enhance stockholder value. Karkus has instead opted to launch a costly and disruptive proxy contest which, if he succeeds, will benefit only him and not his fellow stockholders. We appreciate input from our fellow stockholders, but we will not allow one stockholder to plunder the Company at the expense of all other stockholders.

DON'T GIVE UP CONTROL OF YOUR COMPANY TO AN UNPROVEN SLATE OF

INEXPERIENCED NOMINEES

Mr. Karkus personally claims to own less than 5% of the outstanding shares of your Company, yet he is seeking to gain control of the Company's entire Board. A private investor who has engaged in an opportunistic pattern of buying and selling shares of your Company over the past several years should not be entrusted to run your Company. We believe Karkus is more concerned with personal gain than with the best interests of the Company or our fellow stockholders. We believe that the real motive behind Karkus' campaign is to wrest control of The Quigley Corporation from its true owners, th
'/>"/>

SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. The Quigley Corporation Reports First Quarter 2009 Results
2. Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification
3. The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future
4. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
5. The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
6. The Quigley Corporation Names Gerard M. Gleeson to Succeed Retiring George J. Longo as Chief Financial Officer and Director
7. The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
8. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
9. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
10. Service Corporation International Announces First Quarter 2009 Financial Results
11. Providence Service Corporation Announces Record Revenues and Earnings in the First Quarter of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
(Date:1/22/2015)... has released a new blog post explaining the main features ... , Auto insurance quotes help many drivers find the best ... call an agent or visit an agency for price information. ... http://autocarinsurancebest.com/ . , Every business who relies heavily on ...
(Date:1/22/2015)... 2015 A study recently published ... journal Medicine & Science in Sports & Exercise ... help reduce gastrointestinal (GI) problems associated with physical ... in the double-blind, placebo-controlled study took 10 grams ...
(Date:1/22/2015)... 22, 2015 Four years since the release of ... coincided with the marriage of Avasa & Matthew Love – the ... is scheduled for release through White Swan Records on February 24, ... is a sacred path available to all of us to walk ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store for wedding dresses ... latest collection of wedding dresses , and launches a site-wide ... wedding dress on your big day; the wedding gown is ... wants to find the most suitable wedding dress. Now, we ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... 26, 2010 Global scientific, technical, medical and scholarly ... clinical decision support product, Essential Evidence Plus (EE+), is ... move can now easily find answers to challenging point-of-care ... other Smartphones. EE+ is accessible through ...
... The National Institute of Diabetes and Digestive and Kidney ... has awarded Albert Einstein College of Medicine of Yeshiva ... of its Diabetes Research and Training Center (DRTC). The ... equipment and additional pilot and feasibility studies through the ...
... from biologic meds, study finds , TUESDAY, May 25 ... less likely to be used by American rheumatoid arthritis ... with medical co-payments, a new study reveals. , Biologics, ... treat rheumatoid arthritis when more conventional treatments don,t work. ...
... spent less time in the hospital when treated using ... medical care focusing on increasing muscle motion in ... Kari Hortos, a Michigan State University professor in the ... one of seven site investigators as part of the ...
... ... Shore. , ... May 25, 2010 -- Blue Cross Blue Shield of Massachusetts, Inc. (BCBSMA) and ... Alternative Quality Contract (AQC). The agreement marks the first North Shore physician group ...
... ... Costs. Two of Southern California,s leading physician-governed medical groups, along with Anthem Blue Cross, ... rewards providers for improving patient outcomes, while slowing cost growth. , , ... (PRWEB) May 25, 2010 ...
Cached Medicine News:Health News:Mobile access now available for Essential Evidence Plus 2Health News:NIH awards $10M to Einstein for diabetes research 2Health News:NIH awards $10M to Einstein for diabetes research 3Health News:Out-of-Pocket Costs Limit Access to Arthritis Drugs 2Health News:Hands-on osteopathic treatment cuts hospital stays for pneumonia patients 2Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 2Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 3Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 4Health News:Healthcare Partners, Monarch, and Anthem Blue Cross Chosen for Innovative National Healthcare Program 2Health News:Healthcare Partners, Monarch, and Anthem Blue Cross Chosen for Innovative National Healthcare Program 3Health News:Healthcare Partners, Monarch, and Anthem Blue Cross Chosen for Innovative National Healthcare Program 4
(Date:1/23/2015)... Jan. 23, 2015 Cord Blood America, Inc. ( www.cordblood-america.com ... the "Company")  filed a Preliminary Proxy Statement, Schedule 14A, with ... and provides an update for shareholders detailing why a "YES" ... Dear Shareholders, As we reflect upon ...
(Date:1/23/2015)... 2015  Mallinckrodt plc (NYSE: MNK ) announced ... share repurchase program. The open-ended authorization permits the company ... ordinary shares. "Funding additional initiatives and ... we continue to pursue a range of focused growth ...
(Date:1/23/2015)... Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the development and sale of patented biopharmaceutical medicine, ... pharmaceutical ingredients (API) today announced the business and development ... 1. Following the September 2014 JCM application ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4
... Outcome of Intrauterine Insemination and In Vitro Fertilization Procedures , ... Inc. (OTC Bulletin Board: CDXP) announced today that it has ... regarding a license to develop and market Cordex,s drug candidate, ... drug candidate designed for in vitro (outside of ...
... , SOMERSET, N.J., June 19 , , Dear ... share with you important developments taking place at this critical juncture in ... the first of many as your president. , , Like ... of this company. I want you to know I am fully committed ...
Cached Medicine Technology:Cordex Signs European Development Partnership for ATPotent(TM) Sperm Motility Drug 2Cordex Signs European Development Partnership for ATPotent(TM) Sperm Motility Drug 3Cordex Signs European Development Partnership for ATPotent(TM) Sperm Motility Drug 4Cordex Signs European Development Partnership for ATPotent(TM) Sperm Motility Drug 5Alfacell Provides Shareholder Update 2Alfacell Provides Shareholder Update 3Alfacell Provides Shareholder Update 4Alfacell Provides Shareholder Update 5Alfacell Provides Shareholder Update 6
For the quantitative in vitro determination of Urea in serum, plasma and urine....
For the quantitative in vitro determination of K-glutamyl transferase (K-GT) in serum or plasma....
The CKMB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase MB isoenzyme activity in serum and plasma...
The XCHO method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of cholesterol in serum and plasma....
Medicine Products: